Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate-Reference-Cited by-同舟云学术

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Published:2005-05-01 Issue:9 Volume:11 Page:3425-3432
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Cortes Jorge,Talpaz Moshe,O'Brien Susan,Jones Dan,Luthra Rajyalakshmi,Shan Jenny,Giles Francis,Faderl Stefan,Verstovsek Srdan,Garcia-Manero Guillermo,Rios Mary B.,Kantarjian Hagop

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 239 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients;Drug Research;2023-01-11

2. Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience;Leukemia & Lymphoma;2022-05-02

3. Megakaryocytic Clustering in Chronic Myeloid Leukemia: Can it be a Predictor of Clinical Outcome?;Journal of the College of Physicians and Surgeons Pakistan;2021-01-01

4. Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients;Scientific Reports;2020-11-26

5. SIGNIFICANCE OF ADDITIONAL CHROMOSOMAL ABNORMALITIES FOR THE OUTCOMES AFTER THE SECOND LINE NILOTINIB THERAPY IN THE CHRONIC MYELOID LEUKEMIA PATIENTS;International Journal of Medicine and Medical Research;2019-07-11